TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9510317
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral mesalazine tablets taken three times per day
Study: 26987935
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose factor VIII prophylaxis (10 units kg(‐1) body weight on 2 days a week)
Study: 26987935
Drug: Episodic (On
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic (On demand) factor concentrate in standard recommended doses
Study: 26987935
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose factor VIII prophylaxis
Study: 1488696
Drug: Rice-powder salt
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-powder salt solution (RPSS) - 30 g/l rice powder and 3.5 g/l salt
Study: 1488696
Drug: WHO recommended
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO recommended glucose electrolyte solution (WHO-ORS)
Study: 1488696
Drug: Glycine supplemented
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine supplemented WHO-ORS (G-ORS)
Study: 3566222
Drug: Lysozyme in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysozyme in combination with antibiotics
Study: 3566222
Drug: Antibiotics without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics without lysozyme
Study: 26833752
Drug: 1000 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 U/mL heparin (low dose)
Study: 26833752
Drug: 5000 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 U/mL heparin (high dose)
Study: 22921260
Drug: Nabilone 1-4
Normalized name: nabilone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 1-4 mg/day (n=13)
Study: 20805256
Drug: Continuous antidepressant
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antidepressant use in the placebo arm
Study: 20805256
Drug: Continuous antidepressant
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antidepressant use in the lifestyle arm
Study: 20805256
Drug: Continuous antidepressant
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antidepressant use in the metformin arm
Study: 16197668
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg TID for 7 days (CYC5)
Study: 16197668
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg TID plus Ibuprofen 400 mg TID (CYC5/IBU400)
Study: 16197668
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg TID plus Ibuprofen 800 mg TID (CYC5/IBU800)
Study: 16197668
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CYC5, CYC5/IBU400, CYC5/IBU800)
Study: 12114340
Drug: Respitin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respitin (60 mg/kg once weekly)
Study: 12114340
Drug: Prolastin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin (60 mg/kg once weekly)
Study: 10439755
Drug: Dextromethorphan 40
Normalized name: guaifenesin/dextromethorphan 400 mg-20 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 40 mg orally with premedication, then 40 mg three times per day for 2 days
Study: 28245628
Drug: FOS (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS (8 g/day)
Study: 24720551
Drug: Mavrilimumab (10-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (10-100 mg)
Study: 24720551
Drug: Mavrilimumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (30 mg and 100 mg)
Study: 24720551
Drug: Mavrilimumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (100 mg)
Study: 24410973
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to Mozart K.448 daily before bedtime for at least six months
Study: 12381742
Drug: L-tyrosine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (25 mg/kg body wt)
Study: 12381742
Drug: Polydextrose (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (70 g/l) and L-tyrosine (25 mg/kg body wt) (CHO+Tyr)
Study: 12381742
Drug: Polydextrose (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (70 g/l) (CHO)
Study: 9583332
Drug: Control (nonstudy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonstudy treatments)
Study: 31886744
Drug: Angiotensin Converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin Converting Enzyme inhibitors (ACEis)
Study: 31886744
Drug: RAS molecules
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAS molecules (Angiotensin II, Ang-(1-7))
Study: 31886744
Drug: RAS targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS targeting drugs (ACEis and ARBs)
Study: 30107536
Drug: α‐Cyclodextrin (α‐CD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐Cyclodextrin (α‐CD) 2 g per meal for 2 days
Study: 24106806
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) with propofol
Study: 22728905
Drug: Sequential nephron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential nephron blockade (group 1, n = 85)
Study: 22728905
Drug: Sequential renin-angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential renin-angiotensin system blockade (group 2, n = 82)
Study: 22728905
Drug: Sequential nephron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential nephron blockade (group 1)
Study: 22728905
Drug: Sequential renin-angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential renin-angiotensin system blockade (group 2)
Study: 18345713
Drug: FazaClo (clozapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FazaClo (clozapine orally disintegrating tablets) 100 mg
Study: 18345713
Drug: Clozaril (clozapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozaril (clozapine standard oral tablets) 100 mg
Study: 12430146
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic Therapy (PDT) using a KTP-dye module laser at 630 nm with a primary fluence rate of 100 mW cm(‐2)
Study: 8667280
Drug: IMZ implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ implant system
Study: 8667280
Drug: All implant
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implant systems (TMI, IMZ, BRA)
Study: 6743781
Drug: Investigational oral
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational oral formulation of flurazepam
Study: 27076184
Drug: Monthly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin-piperaquine (DP)
Study: 23588438
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g of maltodextrin twice daily)
Study: 18551024
Drug: Control (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (current medication)
Study: 15843449
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid treatment with 24 hour bed rest
Study: 15843449
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid treatment with normal activity
Study: 15843449
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid treatment (both groups)
Study: 12392871
Drug: Computerized reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized reminders recommending individualized changes in therapy
Study: 6138071
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Vesparax (50 mg hydroxyzine, 150 mg secobarbital, 50 mg brallobarbital)
Study: 28894070
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia (CBT‐I) using mobile SNS, provided once a week for 60 minutes over six weeks
Study: 25918972
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of donepezil and ninjin'yoeito (NYT)
Study: 11845867
Drug: Calcium-channel antagonists
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel antagonists (nifedipine, diltiazem, verapamil)
Study: 10082500
Drug: Quinapril (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (daily dose titrated between 2.5 and 20 mg)
Study: 10082500
Drug: Atenolol (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (daily dose titrated between 12.5 and 100 mg)
Study: 7740014
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch + active gum (group 1)
Study: 7740014
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch + placebo gum (group 2)
Study: 7740014
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch + gum (group 3)
Study: 7362094
Drug: Inhaled diluent
Normalized name: DILUENT
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled diluent
Study: 23834587
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy + SSRI (CBT+SSRI)
Study: 15897160
Drug: Topical immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical immunotherapy with squaric acid dibutylester (SADBE)
Study: 12550076
Drug: MK-677 25mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 25mg daily
Study: 10506267
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (40 mg/kg/day in 3 divided doses; maximum dose 1 g) for 10 days
Study: 27077238
Drug: Siblings Are
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siblings Are Special (SIBS) intervention, 12 weekly afterschool sessions (90 min each) and 3 family nights (2 hr each)
Study: 22592331
Drug: 8 min
Normalized name: INTERLEUKIN 8
DrugBank: Canoctakin (DB18195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 min modified sham feeding (MSF) with 100 ml intragastrically infused liquid (isocaloric, 99 kcal, 100 ml/min)
Study: 22592331
Drug: 8 min
Normalized name: INTERLEUKIN 8
DrugBank: Canoctakin (DB18195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 min modified sham feeding (MSF) with 800 ml intragastrically infused liquid (isocaloric, 99 kcal, 100 ml/min)
Study: 22592331
Drug: 1 min
Normalized name: ZINC OXIDE 182.3 mg in 1 mL TOPICAL CREAM [Mini Hueguard 3-in-1 Mineral SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 min modified sham feeding (MSF) with 100 ml intragastrically infused liquid (isocaloric, 99 kcal, 100 ml/min)
Study: 22592331
Drug: 1 min
Normalized name: ZINC OXIDE 182.3 mg in 1 mL TOPICAL CREAM [Mini Hueguard 3-in-1 Mineral SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 min modified sham feeding (MSF) with 800 ml intragastrically infused liquid (isocaloric, 99 kcal, 100 ml/min)
Study: 22592331
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no oral or gastric stimulation)
Study: 19834718
Drug: Clomiphene 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene 100 mg + delayed low dose gonadotropin + flexible GnRH antagonist administration
Study: 19834718
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist + gonadotropin
Study: 2568848
Drug: Atracurium 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 1.1 mg
Study: 2568848
Drug: Atracurium 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 2.0 mg
Study: 2568848
Drug: Vecuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.25 mg
Study: 2568848
Drug: Vecuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.5 mg
Study: 31813104
Drug: McPhail traps
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: McPhail traps with Bio Anastrepha® combined with different doses of insecticide
Study: 25548124
Drug: Nurse-led problem-solving
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led problem-solving therapy (PST), 12 telephone-based sessions over 6 months.
Study: 21833720
Drug: RP101 (Brivudine)
Normalized name: Brivudine
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP101 (Brivudine) at a dose of 500 mg/day
Study: 21833720
Drug: RP101 (Brivudine)
Normalized name: Brivudine
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP101 (Brivudine) at a dose of 760 mg/day
Study: 16713432
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg plus HRT (conjugated equine estrogen 0.625 mg, medroxyprogesterone 5 mg, elemental calcium 500 mg)
Study: 16713432
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg plus HRT
Study: 7981929
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg resin‐bound diclofenac (resinate)
Study: 7981929
Drug: Enteric‐coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric‐coated tablets containing 75 mg of diclofenac
Study: 7981929
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (resinate and enteric-coated tablets)
Study: 21505058
Drug: Low-dose epoetin-β
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose epoetin-β (35 IU/kg body weight, subcutaneously once weekly for 6 months)
Study: 21505058
Drug: Low-dose epoetin-β
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose epoetin-β
Study: 7484039
Drug: esmolol 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 3 mg.kg‐1
Study: 2150022
Drug: 840 mg
Normalized name: pancreatin 840 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 840 mg stepronin, twice daily for 30 days
Study: 29970156
Drug: Telephone interview
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone interview administration of PROM
Study: 29970156
Drug: Postal questionnaire
Normalized name: APPLE 500 mg in 50 mL TOPICAL SOLUTION [Mostal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postal questionnaire administration of PROM
Study: 29970156
Drug: Online questionnaire
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online questionnaire administration of PROM
Study: 29970156
Drug: Face-to-face interview
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face interview administration of PROM
Study: 25350119
Drug: rectally applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rectally applied tenofovir 1% gel
Study: 21219785
Drug: Prospective ECG-triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective ECG-triggered sequential scan
Study: 18808621
Drug: Body-mind-spirit group
Normalized name: TURPENTINE SPIRITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body-mind-spirit group therapy (10 sessions, 180 minutes each)
Study: 11801708
Drug: 89Sr plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Sr plus 50 mg/m(2) cisplatin
Study: 10395624
Drug: Inulin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (18 g/d)
Study: 6987291
Drug: Ragweed pollen
Normalized name: ragweed pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed pollen extract (0.53 ml of 1:312,500 w/v, mean cumulative dose of 0.094 micrograms of ragweed AgE)
Study: 6987291
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered by the Rinkel method)
Study: 26440516
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D (1g calcium/400IU vitamin D daily)
Study: 20439550
Drug: Navy beans
Normalized name: navy kidney bean allergenic extract
DrugBank: Kidney bean (DB10639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navy beans canned in Canada or UK, homemade navy beans, 300 ml glucose drink (50 g available carbohydrate)
Study: 20439550
Drug: 4 equicaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 equicaloric (300-kcal) treatments of pulses
Study: 17516492
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) for 15 days, 30 min daily at 7,500 lux
Study: 17516492
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 15 days, 30 min daily at 950 lux
Study: 2184488
Drug: Benzodiazepines (flurazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines (flurazepam 15 or 30 mg, triazolam 0.25 or 0.50 mg) and caffeine (250 mg)
Study: 25452222
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and Guided mastery therapy
Study: 25105367
Drug: HIV-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 vaccine
Study: 22299661
Drug: Normal magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal magnesium dialysate (1.8 mg/dL)
Study: 22299661
Drug: Low magnesium
Normalized name: Slow Magnesium Chloride with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low magnesium dialysate (0.6 mg/dL)
Study: 20584515
Drug: PREG-30 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREG-30 (30 mg/d)
Study: 20584515
Drug: DHEA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (400 mg/d)
Study: 20584515
Drug: PREG-200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREG-200 (200 mg/d)
Study: 8045968
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily biosynthetic GH (25 U/m2.week)
Study: 8045968
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily biosynthetic GH (25 U/m2.week)
Study: 17047615
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of atorvastatin
Study: 10722441
Drug: Intravenous (iv)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) ceftriaxone
Study: 3578255
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (n = 53)
Study: 21286008
Drug: GC501 trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC501 trivalent inactivated influenza vaccine
Study: 19394473
Drug: Almond consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond consumption (25 to 168 g/day)
Study: 11426633
Drug: CHOP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP plus INF (5Mu INF s.c. for 5 days on days 22 to 26 of each 28 day cycle, followed by INF 5 million units thrice weekly for 52 weeks for responders)
Study: 9335522
Drug: Docetaxel (Taxotere)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere) - 3 cycles as neoadjuvant treatment
Study: 9335522
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant chemotherapy
Study: 9335522
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cisplatin - ongoing phase I/II dose escalation study
Study: 3767347
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (1 g) plus probenecid
Study: 29943702
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of white blood cell on admission (cutoff points: >8.50×10^9/L)
Study: 29943702
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of white blood cell on admission (cutoff points: <5.60×10^9/L)
Study: 25356826
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg bid for 8 days)
Study: 19897857
Drug: CDB-2914 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 150 mg, in divided doses, administered over three consecutive days starting on Days 21, 49, and 77 after LNG-IUS insertion.
Study: 19897857
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered over the same schedule as CDB-2914.
Study: 18604442
Drug: 30 mg/m2/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/week i.v. epirubicin for 8 weeks
Study: 18604442
Drug: 30 mg/m2/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4-6 months
Study: 18604442
Drug: Oral estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estramustine phosphate (EMP) at a dose of 840 mg/day with weekly and monthly maintenance epirubicin
Study: 8923867
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (leuprolide acetate, 500 micrograms, sc)
Study: 1296590
Drug: HAI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI of floxuridine (FUDR) 0.3 mg/kg/d for 14 days every 4 weeks
Study: 3904438
Drug: Isoxicam, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam, 200 mg once a day
Study: 3904438
Drug: Buffered aspirin,
Normalized name: Buffered Aspirin, buffered 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered aspirin, 3,600 mg per day (900 mg four times a day)
Study: 26309128
Drug: Discontinued oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinued oxytocin infusion